Standout Papers

Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2 2022 2026 2023 2024155
  1. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2 (2022)
    Panke Qu, John P. Evans et al. Cell Host & Microbe
  2. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants (2024)
    Panke Qu, Kai Xu et al. Cell
  3. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants (2023)
    Panke Qu, Julia N. Faraone et al. Cell Reports

Immediate Impact

6 from Science/Nature 40 standout
Sub-graph 1 of 16

Citing Papers

mRNA vaccines for infectious diseases — advances, challenges and opportunities
2024 Standout
Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment
2024 Standout
4 intermediate papers

Works of Panke Qu being referenced

Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants
2024 Standout
A nanoparticle-based HCV vaccine with enhanced potency
2019
and 2 more

Author Peers

Author Last Decade Papers Cites
Panke Qu 640 207 54 121 15 717
Michael T. Boswell 663 181 19 109 11 727
Louise Ormond 532 195 34 69 12 746
Prudence Kgagudi 673 181 16 109 10 776
Bryan A. Johnson 381 240 50 79 20 712
W. Widagdo 619 145 87 219 16 822
Swathi Shrihari 488 179 27 109 12 641
Dionna Scharton 549 174 58 79 14 609
Francisco J. Gutierrez-Alvarez 580 177 20 195 11 706
Frances Ayres 649 178 15 111 7 711
Nathen E. Bopp 604 176 117 122 18 777

All Works

Loading papers...

Rankless by CCL
2026